JA Linscott, H Miyagi, PB Murthy, S Yao… - Current Oncology …, 2024 - Springer
Summary utDNA shows promise for improving all phases of bladder cancer care, paving the way for personalized treatment strategies. Building from current research, future …
Strong epigenetic pan-cancer biomarkers are required to meet several current, urgent clinical needs and to further improve the present chemotherapeutic standard. We have …
FT Zamuner, A Ramos-López… - Biomedical …, 2024 - spandidos-publications.com
Late-stage cancers lack effective treatment, underscoring the need for early diagnosis to improve prognosis and decrease mortality rates. Molecular markers, such as DNA …
LR Nielsen, S Stensgaard, P Meldgaard… - Cancer Treatment and …, 2024 - Elsevier
Background Reliable biomarkers are needed to identify tumor recurrence of non-small cell lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This …
G Berzero, V Pieri, L Palazzo, G Finocchiaro… - Current Opinion in … - journals.lww.com
Monitoring CNVs and hotspot mutations by liquid biopsy is a promising tool to detect minimal residual disease and strengthen response assessment in patients with primary …